论文部分内容阅读
目的初步研究肺癌患者血清中巨噬细胞抑制因子-1(MIC-1)的浓度在肺癌临床中的应用价值。方法采用双抗体夹心ELISA法检测79例肺癌患者、8例肺良性疾病患者及200例正常对照人群血清MIC-1浓度,采用电化学发光免疫分析仪检测上述肺癌患者血清标本CEA、CA125、NSE、SCC、Cyfer21浓度。结果肺癌组患者血清中MIC-1浓度显著高于正常对照组(P<0.001)和良性疾病组(P=0.005);根据ROC曲线和正常人群的MIC-1血清水平,设定1000 pg/ml作为诊断肺癌的临界值时,特异性和敏感性分别为97%和66.6%;MIC-1诊断肺癌的敏感性优于已有标志物CEA、CA125、NSE、SCC、Cyfer21;尤其在Ⅰ期患者中,其敏感性甚至优于上述五种标志物联合诊断(70.8%vs50.0%)。结论本研究首次报道MIC-1成为肺癌新的血清标志物的可能性,在肺癌诊断,特别是在肺癌的早期诊断方面MIC-1显示出良好的应用前景。
Objective To study the clinical value of the concentration of macrophage inhibitory factor-1 (MIC-1) in the serum of lung cancer patients. Methods Serum MIC-1 levels in 79 patients with lung cancer, 8 patients with benign lung disease and 200 normal controls were detected by double antibody sandwich ELISA. Serum CEA, CA125 and NSE were detected by electrochemiluminescence immunoassay. SCC, Cyfer21 concentration. Results The serum concentration of MIC-1 in lung cancer patients was significantly higher than that in normal controls (P <0.001) and benign disease patients (P = 0.005). According to the ROC curve and MIC-1 serum levels in normal subjects, 1000 pg / ml The sensitivity and specificity of MIC-1 in diagnosing lung cancer were 97% and 66.6% respectively. The sensitivity of MIC-1 in diagnosing lung cancer was superior to the existing markers CEA, CA125, NSE, SCC and Cyfer21, especially in stage I patients , Its sensitivity is even better than the combination of the above five markers (70.8% vs50.0%). Conclusions This study is the first to report the potential of MIC-1 as a new serum marker for lung cancer. MIC-1 has shown promising applications in the diagnosis of lung cancer, especially in the early diagnosis of lung cancer.